Aurobindo Pharma Ltd
AUROPHARMAAurobindo Pharma Ltd
AUROPHARMAPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
24.46 | 2.52 | 0.65% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.67 | 5.98 | 0.58% |
Forecast & Ratings
Detailed Forecastfrom 23 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 12,217.23 | 13,999.90 | 15,030.45 | 16,568.15 | 19,721.57 | 23,290.38 | 28,404.97 | 23,891.87 | 25,145.97 | 28,496.32 | ||||||||||
Raw Materials | 5,835.08 | 6,254.98 | 6,743.46 | 7,235.26 | 9,388.19 | 9,837.09 | 10,632.68 | 9,323.60 | 11,702.94 | 22,847.39 | ||||||||||
Power & Fuel Cost | 359.60 | 419.26 | 437.14 | 470.95 | 556.79 | 587.68 | 589.28 | 626.86 | 842.63 | |||||||||||
Employee Cost | 1,302.26 | 1,542.62 | 1,767.76 | 2,130.84 | 2,584.87 | 3,219.18 | 3,535.02 | 3,450.92 | 3,522.25 | |||||||||||
Selling & Administrative Expenses | 1,632.91 | 1,684.89 | 1,969.34 | 2,270.45 | 2,363.93 | 3,162.20 | 3,638.42 | 3,332.28 | 3,705.32 | |||||||||||
Operating & Other expenses | 427.05 | 704.78 | 557.56 | 583.78 | 805.89 | 1,469.35 | 1,536.10 | 2,610.31 | 1,375.27 | |||||||||||
EBITDA | 2,660.33 | 3,393.37 | 3,555.19 | 3,876.87 | 4,021.90 | 5,014.88 | 8,473.47 | 4,547.90 | 3,997.56 | 5,648.93 | ||||||||||
Depreciation/Amortization | 332.61 | 392.37 | 427.63 | 557.97 | 667.95 | 966.71 | 1,055.39 | 1,126.52 | 1,244.58 | 1,512.90 | ||||||||||
PBIT | 2,327.72 | 3,001.00 | 3,127.56 | 3,318.90 | 3,353.95 | 4,048.17 | 7,418.08 | 3,421.38 | 2,752.98 | 4,136.03 | ||||||||||
Interest & Other Items | 159.87 | 256.70 | 66.72 | 77.72 | 262.60 | 305.13 | 74.49 | 48.64 | 140.48 | 255.88 | ||||||||||
PBT | 2,167.85 | 2,744.30 | 3,060.84 | 3,241.18 | 3,091.35 | 3,743.04 | 7,343.59 | 3,372.74 | 2,612.50 | 3,880.15 | ||||||||||
Taxes & Other Items | 592.08 | 719.21 | 759.18 | 818.01 | 726.62 | 897.90 | 2,008.75 | 724.59 | 685.00 | 1,109.66 | ||||||||||
Net Income | 1,575.77 | 2,025.09 | 2,301.66 | 2,423.17 | 2,364.73 | 2,845.14 | 5,334.84 | 2,648.15 | 1,927.50 | 2,770.49 | ||||||||||
EPS | 27.01 | 34.64 | 39.31 | 41.36 | 40.36 | 48.56 | 91.05 | 45.20 | 32.90 | 47.28 | ||||||||||
DPS | 2.25 | 2.50 | 2.50 | 2.50 | 2.50 | 3.00 | 4.00 | 9.00 | 7.50 | 6.00 | ||||||||||
Payout ratio | 0.08 | 0.07 | 0.06 | 0.06 | 0.06 | 0.06 | 0.04 | 0.20 | 0.23 | 0.13 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Aurobindo Pharma Ltd | 35.15 | 2.52 | 0.65% |
Sun Pharmaceutical Industries Ltd | 43.01 | 6.14 | 0.76% |
Cipla Ltd | 40.92 | 4.83 | 0.60% |
Dr Reddy's Laboratories Ltd | 18.77 | 4.50 | 0.64% |
Price Comparison
Compare AUROPHARMA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has decreased by 2.70%
Shareholding Pattern
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 3.13%
Top 5 Mutual Funds holding Aurobindo Pharma Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.9319% | Percentage of the fund’s portfolio invested in the stock 2.17% | Change in the portfolio weight of the stock over the last 3 months -0.14% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/71 (-1) |
Mirae Asset Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7965% | Percentage of the fund’s portfolio invested in the stock 1.61% | Change in the portfolio weight of the stock over the last 3 months 0.24% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 6/100 (+51) |
Quant Mid Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6019% | Percentage of the fund’s portfolio invested in the stock 6.94% | Change in the portfolio weight of the stock over the last 3 months 0.25% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 10/48 (+1) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
AUROPHARMA has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.65%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.49 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateFeb 20, 2024
Dividend/Share
₹1.50
Ex DateEx Date
Feb 20, 2024
Cash Dividend
Ex DateEx DateNov 20, 2023
Dividend/Share
₹3.00
Ex DateEx Date
Nov 20, 2023
Cash Dividend
Ex DateEx DateFeb 17, 2023
Dividend/Share
₹3.00
Ex DateEx Date
Feb 17, 2023
Cash Dividend
Ex DateEx DateJun 6, 2022
Dividend/Share
₹4.50
Ex DateEx Date
Jun 6, 2022
Cash Dividend
Ex DateEx DateFeb 18, 2022
Dividend/Share
₹1.50
Ex DateEx Date
Feb 18, 2022
News & Opinions
News Video
Aurobindo Pharma To Kick-Off Pen-G Production At Andhra Plant, Should You Buy? | Stocks In News
1 month ago•ET NOW
Stocks To Watch: ITC, Vedanta, Aurobindo Pharma, Ramco Cements, Glenmark Pharma, Shree Cement
1 month ago•Bloomberg Quint
Trade setup for Monday: 15 things to know before opening bell
2 months ago•Moneycontrol
Aurobindo Pharma soars 4% on USFDA nod to manufacture Fingolimod capsules
2 months ago•Moneycontrol
US FDA slaps Aurobindo Pharma’s Telangana injectable facility with 7 observations
2 months ago•Moneycontrol
Aurobindo Pharma Q3 Results Review - Niche Products Led Earnings Growth: Motilal Oswal
2 months ago•Bloomberg Quint
Results Review for ONGC, Aurobindo Pharma, Thermax, Bharat Forge, Vinati Organics
2 months ago•Investing.com
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 8.7%, vs industry avg of 8.36%
Decreasing Market Share
Over the last 5 years, market share decreased from 8.16% to 7.7%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -4.47%, vs industry avg of 9.82%